Format

Send to

Choose Destination
Expert Opin Biol Ther. 2015;15(8):1093-9. doi: 10.1517/14712598.2015.1041373. Epub 2015 May 13.

Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer.

Author information

1
Amgen Research (Munich), Global Clinical Development, Therapeutic Area Oncology , Staffelseestraße 2, Munich 81477 , Germany.

Abstract

Various approaches of T-cell-based cancer immunotherapy are currently under investigation, among these are BiTE® (bispecific T-cell engager) antibody constructs, which have a unique design and mechanism of action. They are constructed by genetically linking onto a single polypeptide chain the minimal binding domains of monoclonal antibodies for tumor-associated surface antigens and for the T-cell receptor-associated molecule CD3. Concurrent engagement of the target cell antigen and CD3 leads to activation of polyclonal cytotoxic T-cells, resulting in target cell lysis. Blinatumomab, a BiTE targeting CD19, is being investigated in a broad range of B-cell malignancies and has recently been approved in the USA by the US FDA for Philadelphia chromosome-negative relapsed/refractory B-acute lymphoblastic leukemia under the trade name BLINCYTO™. The BiTE platform is one of the clinically most advanced T-cell immunotherapy options.

KEYWORDS:

BiTE®; T-cells; bispecific antibody; blinatumomab; cancer immunotherapy

PMID:
25971805
DOI:
10.1517/14712598.2015.1041373
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center